SI2374872T1 - Metoda za izražanje aktivnih fuzijskih beljakovin Ig pripadnikov družine receptorjev za TNF na visoki ravni in njihovo čiščenje - Google Patents

Metoda za izražanje aktivnih fuzijskih beljakovin Ig pripadnikov družine receptorjev za TNF na visoki ravni in njihovo čiščenje

Info

Publication number
SI2374872T1
SI2374872T1 SI9931079T SI9931079T SI2374872T1 SI 2374872 T1 SI2374872 T1 SI 2374872T1 SI 9931079 T SI9931079 T SI 9931079T SI 9931079 T SI9931079 T SI 9931079T SI 2374872 T1 SI2374872 T1 SI 2374872T1
Authority
SI
Slovenia
Prior art keywords
purification
high level
level expression
fusion proteins
family member
Prior art date
Application number
SI9931079T
Other languages
English (en)
Other versions
SI2374872T2 (sl
Inventor
Jeffrey Browning
Konrad Miatkowski
Werner Meier
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22345666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2374872(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of SI2374872T1 publication Critical patent/SI2374872T1/sl
Publication of SI2374872T2 publication Critical patent/SI2374872T2/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
SI9931079T 1998-12-17 1999-12-16 Metoda za izražanje aktivnih himernih beljakovin imunoglobulina receptorja limfotoksin-beta na visoki ravni in njihovo čiščenje SI2374872T2 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11275298P 1998-12-17 1998-12-17
EP10011212.7A EP2374872B2 (en) 1998-12-17 1999-12-16 A method for the high level expression of active lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification

Publications (2)

Publication Number Publication Date
SI2374872T1 true SI2374872T1 (sl) 2016-03-31
SI2374872T2 SI2374872T2 (sl) 2019-05-31

Family

ID=22345666

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9931079T SI2374872T2 (sl) 1998-12-17 1999-12-16 Metoda za izražanje aktivnih himernih beljakovin imunoglobulina receptorja limfotoksin-beta na visoki ravni in njihovo čiščenje

Country Status (27)

Country Link
US (3) US7585946B2 (sl)
EP (3) EP2374872B2 (sl)
JP (4) JP4878676B2 (sl)
KR (3) KR20020013482A (sl)
CN (2) CN101289512A (sl)
AT (1) ATE536372T1 (sl)
AU (2) AU777232B2 (sl)
BR (1) BR9916325B1 (sl)
CA (1) CA2354539A1 (sl)
CY (1) CY1117003T1 (sl)
CZ (1) CZ20012156A3 (sl)
DK (2) DK2374872T4 (sl)
EA (1) EA005270B1 (sl)
EE (1) EE200100324A (sl)
ES (1) ES2554482T5 (sl)
HK (2) HK1038244A1 (sl)
HU (1) HUP0200064A2 (sl)
IL (3) IL143670A0 (sl)
IS (1) IS5959A (sl)
NO (1) NO20012991L (sl)
NZ (3) NZ549623A (sl)
PT (1) PT2374872E (sl)
SG (1) SG123531A1 (sl)
SI (1) SI2374872T2 (sl)
SK (1) SK8552001A3 (sl)
TR (2) TR200504220T2 (sl)
WO (1) WO2000036092A2 (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
DE69931944T2 (de) * 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
US7951378B2 (en) 2000-04-28 2011-05-31 Planet Biotechnology Inc. Immunoadhesin comprising a chimeric ICAM-1 molecule produced in a plant
JP4323167B2 (ja) * 2001-01-16 2009-09-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分泌タンパク質を発現する細胞の単離
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
CN101857851A (zh) 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
US7332303B2 (en) 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
WO2005024012A1 (en) * 2003-09-11 2005-03-17 Novozymes A/S Increased expression of a modified polypeptide
US20070099266A1 (en) * 2003-12-23 2007-05-03 Applied Research Systems Ars Holding N.V. Process for the production of tumor necrosis factor-binding proteins
US20110038854A1 (en) * 2006-03-30 2011-02-17 University Of Medicine And Dentistry Of New Jersey Strategy for homo- or hetero-dimerization of various proteins in solution and in cell
KR20090078349A (ko) * 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
WO2008112325A2 (en) * 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
JP2011514895A (ja) * 2008-02-29 2011-05-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 精製免疫グロブリン融合タンパク質およびその精製方法
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
MX2012012528A (es) 2010-04-26 2012-11-23 Novartis Ag Proceso de cultivo celular mejorado.
EP2723759A4 (en) * 2011-06-24 2015-01-28 Reddys Lab Ltd Dr PURIFICATION OF CHIMERIC PROTEIN
JP6223338B2 (ja) 2011-08-17 2017-11-01 アレス トレーディング ソシエテ アノニム 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法
WO2014062535A1 (en) 2012-10-15 2014-04-24 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
TWI745610B (zh) 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
EP3317297A4 (en) 2015-06-30 2019-03-20 Sanford-Burnham Medical Research Institute BTLA AGONIST FUSION PROTEIN AND USES THEREOF
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
CN105400721A (zh) * 2015-12-11 2016-03-16 湖南农业大学 一种快速筛选具有抗菌活性芽孢杆菌的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906096A (en) 1953-12-14 1959-09-29 Pacific Ind Mfg Co Precision control system for press brakes or the like
EP0480923B1 (en) 1989-07-04 1993-09-29 Novo Nordisk A/S Method of producing proteins with fviii activity and/or fviii derivatives
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5670149A (en) 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US7030080B2 (en) 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
ES2157889T3 (es) 1990-06-27 2001-09-01 Biogen Inc Linfotoxina complejada de superficie.
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
NZ260103A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin with alterations in the alpha-helix-1 region
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
EP0620739A4 (en) * 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
WO1994006478A1 (en) 1992-09-22 1994-03-31 Medin Corporation A system for securing medical tools for sterilization
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5726039A (en) 1994-07-21 1998-03-10 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Vectors and transformed host cells for recombinant protein production at reduced temperatures
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
CA2253557A1 (en) * 1996-05-08 1997-11-13 Louis Martin Renzetti Treatment of asthma with tnfr-ig
US6040560A (en) * 1996-10-22 2000-03-21 Philip Morris Incorporated Power controller and method of operating an electrical smoking system
KR100584704B1 (ko) * 1996-10-25 2006-05-30 바이오겐 아이덱 엠에이 인코포레이티드 면역 질환을 치료하기 위한 치료제로서의 가용성 림포톡신-베타 수용체, 항림포톡신 수용체 항체 및 항림포톡신 리간드 항체
US7255854B1 (en) 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
EP0961782A4 (en) * 1996-10-30 2003-07-16 Human Genome Sciences Inc TR2 RECEPTOR OF TUMOR NECROSIS FACTOR IN MAN
CA2272822A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof
US6221608B1 (en) * 1997-01-22 2001-04-24 Ortho Pharmaceutical Corporation Methods for identifying erythropoietin receptor binding protein
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
WO1999053059A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
AU4314299A (en) 1998-05-29 1999-12-13 Genentech Inc. Cell culture process for producing glycoproteins
DE69931944T2 (de) 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US9086881B2 (en) 2012-06-29 2015-07-21 Intel Corporation Mechanism for facilitating write tracking for following data eye movements across changing thermal conditions in memory systems

Also Published As

Publication number Publication date
AU2005200042A1 (en) 2005-02-03
ES2554482T3 (es) 2015-12-21
JP2010158252A (ja) 2010-07-22
IL229738A0 (en) 2014-01-30
DK2374872T4 (en) 2019-04-23
US20100136625A1 (en) 2010-06-03
KR20020013482A (ko) 2002-02-20
CA2354539A1 (en) 2000-06-22
NO20012991L (no) 2001-08-17
KR20070091227A (ko) 2007-09-07
WO2000036092A3 (en) 2000-11-23
EP3006563A1 (en) 2016-04-13
EP2374872A2 (en) 2011-10-12
DK2374872T3 (en) 2015-12-14
NZ538599A (en) 2007-11-30
AU777232B2 (en) 2004-10-07
BR9916325A (pt) 2001-10-02
BR9916325B1 (pt) 2011-06-28
EP2374872B1 (en) 2015-11-25
CN101289512A (zh) 2008-10-22
EA005270B1 (ru) 2004-12-30
PL348816A1 (en) 2002-06-17
NZ529276A (en) 2005-03-24
WO2000036092A2 (en) 2000-06-22
SG123531A1 (en) 2006-07-26
JP2014239697A (ja) 2014-12-25
US20130196376A1 (en) 2013-08-01
EP1141248A2 (en) 2001-10-10
WO2000036092A9 (en) 2002-08-22
ES2554482T5 (es) 2019-07-18
NO20012991D0 (no) 2001-06-15
SK8552001A3 (en) 2001-12-03
DK1141248T3 (da) 2012-03-12
IS5959A (is) 2001-05-31
US8283138B2 (en) 2012-10-09
NZ549623A (en) 2008-05-30
EP2374872A3 (en) 2011-10-19
KR20060084860A (ko) 2006-07-25
EA200100670A1 (ru) 2001-12-24
EP2374872B2 (en) 2019-02-20
IL143670A0 (en) 2002-04-21
JP2013116118A (ja) 2013-06-13
JP2003517277A (ja) 2003-05-27
HK1223398A1 (zh) 2017-07-28
JP4878676B2 (ja) 2012-02-15
JP5777171B2 (ja) 2015-09-09
EP1141248B1 (en) 2011-12-07
CY1117003T1 (el) 2017-04-05
US20020039580A1 (en) 2002-04-04
IL205698A (en) 2015-11-30
AU2005200042B2 (en) 2008-05-01
HUP0200064A2 (en) 2002-05-29
TR200101703T2 (tr) 2002-05-21
PT2374872E (pt) 2015-12-09
US8709759B2 (en) 2014-04-29
EE200100324A (et) 2002-10-15
ATE536372T1 (de) 2011-12-15
TR200504220T2 (tr) 2007-04-24
HK1038244A1 (en) 2002-03-08
CN1333819A (zh) 2002-01-30
CZ20012156A3 (cs) 2001-09-12
CN100387708C (zh) 2008-05-14
KR100732934B1 (ko) 2007-06-29
AU2364400A (en) 2000-07-03
US7585946B2 (en) 2009-09-08
SI2374872T2 (sl) 2019-05-31

Similar Documents

Publication Publication Date Title
SI2374872T1 (sl) Metoda za izražanje aktivnih fuzijskih beljakovin Ig pripadnikov družine receptorjev za TNF na visoki ravni in njihovo čiščenje
IL121614A0 (en) System for the expression of heterologous antigens as fusion proteins
SG47996A1 (en) Method for culturing animal cells under embedded conditions
ZA977948B (en) Process for the control of weeds.
GB2331164B (en) Adaptive control method for cyclic signal
ITBO930297A0 (it) Metodo per il controllo ottico per il riempimento di sigarette.
IL122898A0 (en) Allergan -XCD32 fusion proteins
ZA985026B (en) Method for enhancing the activity of an enzyme.
ZA983471B (en) Method for cleavage of fusion proteins
FR2730835B1 (fr) Procede d'adaptation automatique des parametres d'une interface
ZA988025B (en) Method for enhancing the activity of an enzyme.
FR2701953B1 (fr) Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant.
EP1017279A4 (en) METHOD FOR REGULATING THE TRKA EXPRESSION
IT1285726B1 (it) Metodo per il controllo dei rifornimenti di carburante e relativa apparecchiatura.
ATE293987T1 (de) Methode zur mobilisierung hematopoietischer stammzellen
US5807733A (en) Mammalian prostaglandin H synthase-2 fusion proteins
ZA979101B (en) Method of determining suspension movement.
EP0623971A3 (en) Improved method of connecting heating elements.
GB2329609B (en) Method of quality control
ZA996344B (en) Method of waste control.
GB9806698D0 (en) Chimeric antibodies
GB9812972D0 (en) Method for the alignment of lens arrays
GB9519057D0 (en) Method for the fabrication of electrodes
IL118112A0 (en) Method for the production of recombinant glucocerobrosidase protein
FR2771578B1 (fr) Procede de delivrance de courriers electroniques